Back to results
US 9,066,961 B2Granted
Medicament for LCT poisoning
AssigneeJohannes Gutenberg-Universitaet Mainz
InventorsChristoph Von Eichelstreiber, Jessica Reineke, Stefan Tenzer, Hansjoerg Schild, Maja Rupnik
Life of this patent
Estimating the term…
Abstract
The medicament for the prevention or the relief of poisoning by large clostridial cytotoxins (LCTs), in particular Clostridium difficile toxins A and B (TcdA and TcdB), is characterized by containing as active ingredient at least one effector, namely an inhibitor or activator of the autocatalytic protease activity of LCTs (large clostridial cytotoxins).
Claims10
Method for treating a patient suffering from clostridium infection, comprising:
- selecting one or more activators of an autocatalytic protease activity of LCTs (=large clostridial cytotoxin) that interact with one or more protease of Clostridium difficile toxin A (TcdA), Clostridium difficile toxin B (TcdB), Clostridium sordellii lethal toxin (TcsL) or Clostridium novyi α-toxin Tcn(α) and that initiate a protease activity of said one or more protease, based on detecting the splitting off of an N-terminal fragment of the LCT,
- administering to said patient a medicament comprising said one or more activators, wherein the one or more activators are administered in an amount effective to activate and bring about the autocatalytic cleavage of said LCTs in the patient's gut outside a cell of the patient,
- wherein the protease activity of said one or more protease is initiated and
- wherein a cytotoxically effective fragment of said Clostridium difficile toxin A (TcdA), Clostridium difficile toxin B (TcdB), Clostridium sordellii lethal toxin (TcsL) or Clostridium novyi α-toxin (Tcnα), respectively, is auto catalytically split off via said protease activity in the patient's gut outside the cell of the patient.
1 more element
Dependencies are inferred from the claim text.